Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 18;24(8):1540.
doi: 10.3390/molecules24081540.

Preparation of Benzothiazolyl-Decorated Nanoliposomes

Affiliations

Preparation of Benzothiazolyl-Decorated Nanoliposomes

Spyridon Mourtas et al. Molecules. .

Abstract

Amyloid β (Aβ) species are considered as potential targets for the development of diagnostics/therapeutics towards Alzheimer's disease (AD). Nanoliposomes which are decorated with molecules having high affinity for Aβ species may be considered as potential carriers for AD theragnostics. Herein, benzothiazolyl (BTH) decorated nanoliposomes were prepared for the first time, after synthesis of a lipidic BTH derivative (lipid-BTH). The synthetic pathway included acylation of bis(2-aminophenyl) disulfide with palmitic acid or palmitoyl chloride and subsequent reduction of the oxidized dithiol derivative. The liberated thiols were able to cyclize to the corresponding benzothiazolyl derivatives only after acidification of the reaction mixture. Each step of the procedure was monitored by HPLC analysis in order to identify all the important parameters for the formation of the BTH-group. Finally, the optimal methodology was identified, and was applied for the synthesis of the lipid-BTH derivative. BTH-decorated nanoliposomes were then prepared and characterized for physicochemical properties (size distribution, surface charge, physical stability, and membrane integrity during incubation in presence of buffer and plasma proteins). Pegylated BTH-nanoliposomes were demonstrated to have high integrity in the presence of proteins (in comparison to non-peglated ones) justifying their further exploitation as potential theragnostic systems for AD.

Keywords: amyloid β; benzothiazoles; functionalization; nanoliposomes; targeting.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1
Scheme 1
Synthesis of bis(2-aminophenyl) disulfide.
Scheme 2
Scheme 2
Synthetic method for the formation of Palm-BTH; Compound 3 was used either as palmitic acid (X=OH) when N,N′-diisopropylcarbodiimide (DIC) was used as a condensing agent, or as palmitoyl chloride (X=Cl) when triethylamine (NEt3) was used as a base.
Figure 1
Figure 1
HPLC analysis during the reaction between bis(2-aminophenyl) disulfide and palmitic acid in tetrahydrofuran (THF), using DIC as condensing agent; (A) t=1d at rt; (B) t=3d at rt; Column: LiChrospher® 100 RP-18 (5 µm) LiChroCART® 250-4; Mobile phase: THF/H2O; Gradient: 50% THF to 100% THF in 30 min; Flow rate: 1ml/min; Detection at 254 nm.
Figure 2
Figure 2
HPLC analysis of (A) the final mixture of 4a+4b after 7 days reaction at rt of bis(2-aminophenyl) disulfide and palmitic acid in THF by using DIC as condensing agent; (B) during the reduction of 4a+4b with NaBH4; (C) after the reduction of 4a+4b with NaBH4 without subsequent acidification of the mixture; (D) after the reduction of 4a+4b with NaBH4 and subsequent acidification with AcOH; Column: LiChrospher® 100 RP-18 (5 µm) LiChroCART® 250-4; Mobile phase: THF/H2O; Gradient: 50% THF to 100% THF in 30 min; Flow rate: 1mL/min; Detection at 254nm.
Figure 3
Figure 3
HPLC analysis of (A) the reaction mixture product between bis(2-aminophenyl) disulfide and palmitoyl chloride in presence of NEt3; (B) the reaction mixture after reduction with NaBH4 and acidification with AcOH; Column: LiChrospher® 100 RP-18 (5 µm) LiChroCART® 250-4; Mobile phase: THF/H2O; Gradient: 50% THF to 100% THF in 30 min; Flow rate: 1mL/min; Detection at 254 nm.
Scheme 3
Scheme 3
Synthetic method for the formation of Lipid-COOH; R=CH3-(CH2)14-.
Scheme 4
Scheme 4
Synthetic method for the formation of lipid-BTH.
Figure 4
Figure 4
(A) HPLC analysis of purified lipid-BTH.; Column: LiChrospher® 100 RP-18 (5 µm) LiChroCART® 250-4; Mobile phase: THF/H2O; Gradient: 50% THF to 100% THF in 30 min; Flow rate: 1ml/min; Detection at 254nm; (B) ESI-MS of lipid-BTH.
Figure 5
Figure 5
Size (d-hydrodynamic mean diameter, nm) and pdi values of the LIP1–LIP6 prepared dispersions, in PBS buffer 7.4 at a lipid concentration of 5 mg/mL, during storage at 4 °C. Each value is the mean of at least 5 different measurements and bars are the SD values of each mean.
Figure 6
Figure 6
Integrity of non-pegylated BTH-nanoliposomes (LIP1 and LIP2) and pegylated BTH-nanoliposomes (LIP5 and LIP6) and their corresponding control nanoliposomes (with no BTH on their surface), during incubation in buffer (A) or FCS (80% v/v) (B) at 37 °C. Each data point is the mean of at least 3 different experiments and the bar is the SD of the mean.
Figure 7
Figure 7
DSC thermographs of control nanoliposomes (no BTH) (a); LIP1 (10% BTH) (b); and LIP2 (20% BTH) (c).

Similar articles

Cited by

References

    1. Sanabria-Castro A., Alvarado-Echeverría I., Monge-Bonilla C. Molecular Pathogenesis of Alzheimer’s Disease: An Update. Ann. Neurosci. 2017;24:46–54. doi: 10.1159/000464422. - DOI - PMC - PubMed
    1. Kumar K., Kumar A., Keegan R.M., Deshmukh R. Recent advances in the neurobiology and neuropharmacology of Alzheimer’s disease. Biomed. Pharmacother. 2018;98:297–307. doi: 10.1016/j.biopha.2017.12.053. - DOI - PubMed
    1. Citron M. Alzheimer’s disease: Strategies for disease modification. Nat. Rev. Drug Discov. 2010;9:387–398. doi: 10.1038/nrd2896. - DOI - PubMed
    1. Chopra K., Misra S., Kuhad A. Current perspectives on pharmacotherapy of Alzheimer’s disease. Expert Opin. Pharmacother. 2011;12:335–350. doi: 10.1517/14656566.2011.520702. - DOI - PubMed
    1. Folch J., Petrov D., Ettcheto M., Abad S., Sánchez-López E., García M.L., Olloquequi J., Beas-Zarate C., Auladell C., Camins A. Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment. Neural. Plast. 2016;2016:8501693. doi: 10.1155/2016/8501693. - DOI - PMC - PubMed

LinkOut - more resources